Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
  • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
  • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
  • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K31/52—Purines, e.g. adenine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Definitions

• Hyperuricemia is defined by values of blood uric acid over 6.8 to 7.0 mg/dL in men or over 6 mg/dL in women.
• Hyperuricemia and metabolic disorders associated with hyperuricemia, such as gout affect 3 to 5 million individuals in the United States. In the United States, African Americans are twice as likely as Caucasian Americans to have gout. Further, gout and hyperuricemia have become common in China, Japan, Polynesia and urban sub-Saharan Africa, with rates of gout approximately doubling between 1990 and 2010. This rise in the incidence of the disease is believed to be due to a longer life expectancy, changes in diet, alcohol consumption and an increase in diseases associated with gout, such as metabolic syndrome, renal insufficiency and hypertension. A number of factors have been found to influence rates of gout, including age, race, and the season of the year. In men over the age of 30 and women over the age of 50, prevalence of gout is approximately two percent.
• the metabolic disorders associated with hyperuricemia include not only gout, but also painful attacks of acute, monarticular, inflammatory arthritis due to uric acid crystals, deposition of urate crystals in joints, deposition of urate crystals in renal parenchyma, urolithiasis, nephrolithiasis and gouty nephropathy. Long term nephrolithiasis and gouty nephropathy are known to increase the risk of kidney damage and kidney failure.
• Gout is a medical condition usually characterized by recurrent TWJ 10477P00090PC attacks of acute inflammatory arthritis.
• the metatarsal-phalangeal joint at the base of the big toe is the most commonly affected (in. about 50% of cases).
• gout may also present as tophi, kidney stones or urate nephropathy. Gout is believed to be caused by elevated levels of uric acid in the blood which crystallize and are deposited in joints, tendons, and surrounding tissues.
• urate-lowering agents such as: 1 ) xanthine oxidase inhibitors, such as allopurinol and febuxostat; 2) uricosuric agents, such as sulphinpyrazone, benzbromarone and probenecid; 3) urate oxidases, such as pegloticase, puricase, rasburicase and pegylated uricase; and 4) fenofibrate.
• urate-lowering agents such as: 1 ) xanthine oxidase inhibitors, such as allopurinol and febuxostat; 2) uricosuric agents, such as sulphinpyrazone, benzbromarone and probenecid; 3) urate oxidases, such as pegloticase, puricase, rasburicase and pegylated uricase; and 4) fenofibrate.
• the symptoms of acute gout may be controlled by anti-inflammatory agents, such as: 1 ) non-steroidal anti-inflammatory drugs (NSAIDs), such as indomethacin and ibuprofen; 2) corticosteroids; and 3) colchicine.
• NSAIDs non-steroidal anti-inflammatory drugs
• Bringing the blood uric acid levels back to the normal range may decrease the incidence of the recurrent acute gout and prevent other metabolic disorders associated with hyperuricemia.
• probenecid may affect the excretion of such drugs as captopril, indomethacin, ketoprofen, ketorolac, naproxen, TWI10477P00090PC cephalosporins, quinolones, penicillins, methotrexate, zidovudine, gancyclovir and acyclovir.
• NSAIDs Long term use of NSAIDs may lead to side effects, including ulcer perforation and upper gastrointestinal bleeding.
• the present invention provides therapeutic methods for the treatment and/or prevention of hyperuricemia and metabolic disorders associated with hyperuricemia, such as gout, gout arthritis, gout flares, uric acid nephrolithiasis and gouty nephropathy.
• the methods are especially suitable for hyperuricemic patients who have inadequate medical control or cannot tolerate the currently available urate-lowering and anti-inflammatory therapies.
• the methods of using a therapeutically effective amount of diacerein, rhein, or a pharmaceutically acceptable salt, an analog, a prodrug, or an active metabolite thereof to treat and/or prevent hyperuricemia and metabolic disorders associated with hyperuricemia offer unexpected advantages in decreasing the blood uric acid levels as compared to the use of the currently available pharmaceutical agents.
• Diacerein [4, 5- bis(acetyloxy)-9, 10- dioxo-2-anthracene carboxylic acid] is a highly purified anthraquinone derivative. It has been approved as a SYmptomatic Slow-Acting Drug in Osteoarthritis (SYSADOA) in several countries. Rhein is the major active metabolite of diacerein. Diacerein has been demonstrated to inhibit the synthesis and activity of proinflammatory TW110477P00090PC cytokines such as interleukin-1 (IL-1 ), TNF-a and interleukin-6 (IL-6).
• IL-1 interleukin-1
• IL-6 interleukin-6
• diacerein can decrease and maintain blood uric acid levels within the normal range during the treatment period of patients with hyperuricemia and metabolic disorders associated with hyperuricemia. Further, diacerein can also prevent the recurrence of acute gout arthritis and gout flares, whether it is used as the sole active drug (i.e., diacerein monotherapy) or in a combination with other urate-lowering and/or anti-inflammatory agents.
• the invention provides a method of treating and/or preventing hyperuricemia or a metabolic disorder associated with hyperuricemia comprising administering to a patient in need thereof a therapeutically effective amount of a compound selected from the group consisting of: 1 ) diacerein, 2) rhein, and 3) a pharmaceutically acceptable salt, an analog, a prodrug, or an active metabolite thereof.
• the method of treating and/or preventing hyperuricemia or a metabolic disorder associated with hyperuricemia may further comprise administering to said patient at least one additional therapeutic agent selected from the group consisting of anti-inflammatory agents and urate-lowering agents.
• the invention provides a method of improving blood uric acid level control in a patient with gout, hyperuricemia or a metabolic disorder associated with hyperuricemia comprising administering to said patient a therapeutically effective amount of a compound selected from the TWI 10477P00090PC group consisting of: 1) diacerein, 2) rhein, and 3) a pharmaceutically acceptable salt, an analog, a prodrug, or an active metabolite thereof.
• the invention provides a method of treating and/or preventing hyperuricemia or a metabolic disorder associated with hyperuricemia in a patient receiving a urate-lowering agent or an anti-inflammatory agent, comprising administering to said patient a therapeutically effective amount of a compound selected from the group consisting of: 1 ) diacerein, 2) rhein, and 3) a pharmaceutically acceptable salt, an analog, a prodrug, or an active metabolite thereof.
• the invention provides a method of treatment for hyperuricemia or a metabolic disorder associated with hyperuricemia in a patient with poor tolerance to therapeutic agents selected from the group consisting of anti-inflammatory agents and urate-lowering agents, comprising administering to said patient a therapeutically effective amount of a compound selected from the group consisting of: 1 ) diacerein, 2) rhein, and 3) a pharmaceutically acceptable salt, an analog, a prodrug, or an active metabolite thereof.
• Figure 1 is a graph demonstrating blood uric acid levels in male patients treated with either diacerein or placebo.
• Figure 2 is a graph demonstrating blood uric acid levels in female patients treated with either diacerein or placebo.
• diacerein, rhein, or a pharmaceutically acceptable salt, an analog, a prodrug, or an active metabolite thereof can be used for the treatment and/or prevention of hyperuricemia and metabolic disorders associated with hyperuricemia, such as gout, gout arthritis, gout flares, uric acid nephrolithiasis and gouty nephropathy.
• Treatment of hyperuricemia aims to reduce the blood levels of uric acid to the normal range, in humans, the upper end of the normal range of blood uric acid levels is about 6 mg/dL for women and about 7.0 mg/dL for men. These ranges are subject to change depending on updated clinical guidelines.
• Treatment of gout aims to relieve pain and inflammation of the acute attack and reduce the incidence of recurrent attacks.
• diacerein 5- bis(acetyloxy)-9, 10- dioxo-2-anthracene carboxylic acid
• diacerein 5- bis(acetyloxy)-9, 10- dioxo-2-anthracene carboxylic acid
• Diacerein directly inhibits ⁇ _-1 ⁇ synthesis and modulates IL-1 ⁇ induced activities. Diacerein has been shown to have disease modifying effect in experimental models of osteoarthritis and in human subjects with finger joint and knee osteoarthritis. IL-1 ⁇ plays a fundamental role in osteoarthritis pathophysiology and cartilage destruction. ⁇ _-1 ⁇ also promotes the expression of inducible nitric oxide synthase, and increases the release of prostaglandin
• salts include salts of acidic or basic groups.
• pharmaceutically acceptable salts include those derived from inorganic acids, such as hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids, such as acetic; propionic; isobutyric; maleic; malonic; benzoic; succinic; suberic; fumaric; mandelic; phthalic; benzenesulfonic; toluenesulfonic, including TWI10477P00090PC p-toluenesulfonic, m-toluenesulfonic, and o-toluenesulfonic; citric; tartaric; methanesu
• prodrug refers to a pharmacologically inactive derivative of an active drug designed to convert into the active drug through in vivo physiological action, such as hydrolysis, metabolism and the like.
• urate-lowering agent refers to a drug used to treat gout and hyperuricemia by lowering uric acid levels in the blood.
• examples of the currently available urate-lowering agents include, but not limited to, 1 ) xanthine oxidase inhibitors, such as allopurino! and febuxostat; 2) uricosuric agents, such as sulphinpyrazone, benzbromarone and probenecid; 3) urate oxidase inhibitors, such as pegloticase, puricase, rasburicase and pegylated uncase; and 4) fenofibrate. Those drugs can be given alone or in a combination.
• anti-inflammatory agent refers to a drug used to treat inflammatory symptoms of gout and hyperuricemia.
• examples of the currently available anti-inflammatory agents include, but not limited to, 1 ) non-steroidal anti-inflammatory drugs (NSAIDs), such as indomethacin and ibuprofen, 2) corticosteroids, and 3) colchicine.
• NSAIDs non-steroidal anti-inflammatory drugs
• treatment and “treating” include inhibiting the disease or condition, causing a reduction in severity and/or frequency of symptoms, elimination of symptoms and/or underlying cause, TWI 10477P00090PC prevention of the occurrence of symptoms and/or their underlying cause, ameliorating and/or improving a patient's condition.
• "treating" a patient with said compositions of the invention includes prevention of a particular disorder in a susceptible individual, as well as management of a clinically symptomatic individual to inhibit or cause regression of a disorder or disease, and maintenance of the current state and/or prevention of a progression of a disorder or disease.
• Treatment can include prophylaxis, therapy, or cure.
• the term "therapeutically effective amount" of the compounds and/or pharmaceutical compositions of the invention refers to a sufficient amount of the compound and/or composition to treat, inhibit, ameliorate or prevent hyperuricemia or metabolic disorders associated with hyperuricemia, at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the compounds and/or compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
• the specific effective dose level for any particular patient will depend upon a variety of factors, including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts.
• the term "co-administered” includes administration of diacerein and at least one urate-lowering agent and/or anti-inflammatory agent either as a single composition or as separate compositions.
• Diacerein and at least one urate-lowering agent and/or anti-inflammatory agent may be administered by the same or different routes of administration and/or at the same or different time or dosing regimens.
• the invention provides a method of treating and/or preventing hyperuricemia or a metabolic disorder associated with hyperuricemia comprising administering to a patient in need thereof a therapeutically effective amount of a compound selected from the group consisting of: 1 ) diacerein, 2) rhein, and 3) a pharmaceutically acceptable salt, an analog, a prodrug, or an active metabolite thereof.
• the therapeutically effective amount of diacerein is from 10 to 200 mg per day.
• the therapeutically effective amount of a pharmaceutically acceptable salt, an analog, a prodrug, or an active metabolite of diacerein is equivalent to from 10 to 200 mg of diacerein base per day.
• the active metabolite of diacerein is monoacetyl rhein or rhein.
• the metabolic disorder associated with hyperuricemia is selected from the group consisting of acute gout, chronic gout, TWI10477P00090PC gout arthritis, gout flares, uric acid nephrolithiasis and gouty nephropathy.
• the method of treating and/or preventing hyperuricemia or a metabolic disorder associated with hyperuricemia may further comprise administering to said patient at least one additional therapeutic agent selected from the group consisting of anti-inflammatory agents and urate-lowering agents.
• the invention provides a method of improving blood uric acid level control in a patient with gout, hyperuricemia or a metabolic disorder associated with hyperuricemia comprising administering to said patient a therapeutically effective amount of a compound selected from the group consisting of: 1 ) diacerein, 2) rhein, and 3) a pharmaceutically acceptable salt, an analog, a prodrug, or an active metabolite thereof.
• the invention provides a method of treating or preventing hyperuricemia or a metabolic disorder associated with hyperuricemia in a patient receiving a urate-lowering agent or an anti-inflammatory agent, comprising administering to said patient a therapeutically effective amount of a compound selected from the group consisting of: 1 ) diacerein, 2) rhein, and 3) a pharmaceutically acceptable salt, an analog, a prodrug, or an active metabolite thereof.
• the method of treating or preventing hyperuricemia or a metabolic disorder associated with hyperuricemia in a patient receiving a urate-lowering agent or an anti-inflammatory agent reduces blood levels of uric acid below the upper end of the normal range in said TWI10477P00090PC patient.
• the provided methods of treating and/or preventing hyperuricemia or a metabolic disorder associated with hyperuricemia do not require and do not comprise a co-administration of any additional therapeutic agents, including but not limited to, urate-lowering agents, anti-inflammatory agents, inhibitors of pH-activated proteases and others.
• the invention provides a method of treatment for hyperuricemia or a metabolic disorder associated with hyperuricemia in a patient with poor tolerance to therapeutic agents selected from the group consisting of anti-inflammatory agents and urate-lowering agents, comprising administering to said patient a therapeutically effective amount of a compound selected from: 1 ) diacerein, 2) rhein, and 3) a pharmaceutically acceptable salt, an analog, a prodrug, or an active metabolite thereof.
• the anti-inflammatory agent is selected from the group consisting of non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, colchicines and a combination thereof.
• NSAIDs non-steroidal anti-inflammatory drugs
• corticosteroids corticosteroids
• colchicines colchicines
• NSAIDs include, but are not limited to, arylalkanoic acids such as acetaminophen; 2-arylpropionic acids such as ibuprofen, ketorolac and naproxen; n-arylanthranilic acids such as mefenamic acid, TWI10477P00090PC meclofenamic acid; oxicams such as piroxicam, meloxicam; arylalkanoic acids such as diclofenac, eiodoiac, indomethacin, sulindac; and COX -2 inhibitors such as celecoxib.
• arylalkanoic acids such as acetaminophen
• 2-arylpropionic acids such as ibuprofen, ketorolac and naproxen
• n-arylanthranilic acids such as mefenamic acid, TWI10477P00090PC meclofenamic acid
• oxicams such as piroxicam, meloxicam
• the urate-lowering agent is selected from the group consisting of xanthine oxidase inhibitors, uricosuric agents, urate oxidases, urinary alkalinizers and fenofibrate.
• Examples of xanthine oxidase inhibitors include, but are not limited to, allopurinol, oxypurinol and febuxostat.
• Examples of uricosuric agents include, but are not limited to, buco!ome, sulphinpyrazone, benzbromarone and probenecid.
• Examples of urate oxidases include, but are not limited to, pegloticase, puricase, rasburicase, uricase and pegylated uricase.
• urinary alkalinizers include, but are not limited to, sodium hydrogen carbonate, potassium citrate and sodium citrate.
• the method of treatment lowers blood levels of uric acid; and/or decreases inflammatory effects of gout arthritis and gout flares induced by hyperuricemia; and/or dissolves kidney stones; and/or reduces the recurrence rate of acute inflammatory arthritis induced by hyperuricemia: and/or prevents the recurrent hyperuricemia; and/or slows down the progression of urate nephropathy in said patient.
• the method of treatment reduces blood levels of uric acid below the upper end of the normal range in said patient.
• Diacerein and an anti-infiammatory agent and/or a u rate-lowering agent may be contained in a single formulation or may be co-administered as separate formulations.
• the invention also provides pharmaceutical compositions for treating and/or preventing hyperuricemia or a metabolic disorder associated with hyperuricemia in a patient comprising a therapeutically effective amount of a compound selected from the group consisting of: 1 ) diacerein, 2) rhein, and 3) a pharmaceutically acceptable salt, an analog, a prodrug, or an active metabolite thereof.
• the therapeutically effective amount of diacerein is from 10 to 200 mg per day.
• the therapeutically effective amount of a pharmaceutically acceptable salt, an analog, a prodrug, or an active metabolite of diacerein is equivalent to from 10 to 200 mg of diacerein base per day.
• compositions comprising: 1 ) diacerein, rhein, or a pharmaceutically acceptable salt, a prodrug, or an active metabolite thereof, and 2) at least one additional therapeutic agent.
• the additional therapeutic agent is selected from the group consisting of anti-inflammatory agents and urate-lowering agents.
• the additional therapeutic agent is selected from the group consisting of: 1 ) xanthine oxidase inhibitors; 2) uricosuric agents; 3) urate oxidase inhibitors; 4) fenofibrate; 5) NSAIDs; 6) TWI10477P00090PC corticosteroids, and 7) colchicine.
• the additional active ingredient can be present in a controlled-release dosage form or in an immediate release dosage form.
• diacerein When administered to a patient in need thereof, diacerein, its pharmaceutically acceptable salts, prodrugs, or active metabolites can be prepared as pharmaceutical compositions.
• the pharmaceutical composition can further include a pharmaceutically acceptable carrier, and can be in solid or liquid form, including but not limited to, tablets, powders, capsules, pellets, solutions, suspensions, elixirs, emulsions, gels, creams; patch, or suppositories, including rectal and urethral suppositories.
• a pharmaceutically acceptable carrier including but not limited to, tablets, powders, capsules, pellets, solutions, suspensions, elixirs, emulsions, gels, creams; patch, or suppositories, including rectal and urethral suppositories.
• the term "pharmaceutically acceptable carrier” refers to a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material.
• a pharmaceutically acceptable carrier is compatible with the other ingredients of the composition, with the mode of administration, and not injurious to the patient.
• a pharmaceutically acceptable carrier may be either aqueous or non-aqueous.
• Pharmaceutically acceptable carriers include gums, starches, sugars, ceilulosic materials, and mixtures thereof.
• materials which can serve as pharmaceutically-acceptable carriers include, but are not limited to: (a) sugars, such as lactose, glucose and sucrose, (b) starches, such as corn starch and potato starch; (c) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (d) powdered tragacanth; (e) malt; (f) gelatin; (g) talc; (h) excipients, such as cocoa TWI10477P00090PC butter and suppository waxes; (i) oils, such as peanut oil, cottonseed oil, safflo er oil, sesame oil, olive oil, corn oil and soybean oil; (j) glycols, such as propylene glycol; (k) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (1) esters, such as ethyl oleate and e
• compositions of the invention may be administered using any means known in the art, including but not limited to oral, nasal, parenteral, topical, transdermal, or rectal routes of administration.
• the compositions are adapted for oral or topical administration.
• the active ingredient of the composition can be formulated with suitable excipients for the preparation of tablets, capsules, pellets, troches, lozenges, solutions, powders or granules, suspensions, hard or soft capsules, patches and any other suitable forms.
• suitable excipients for the preparation of tablets, capsules, pellets, troches, lozenges, solutions, powders or granules, suspensions, hard or soft capsules, patches and any other suitable forms.
• Subjects Male or female type 2 diabetes patients (BMI ⁇ 35 kg/m 2 ) with micro-albuminuria.
• Procedure This was a Phase II, prospective, randomized, double-blind, and parallel comparison study comparing diacerein 50 mg bid (twice a day) versus placebo to albuminuria in patients with type 2 diabetes mellitus.
• ARBs anti-proliferatives
• hypoglycemic medications were maintained during the study period.
• the class and/or dosage were changed if clinically indicated.
• An introduction of a new treatment or any regimen change to the pre-existing co-medication that had hypoglycemic or hyperglycemic potential was allowed during the study with the consent of the clinical investigator.
• the hyperuricemia sub-group was assembled from among the subjects with baseline blood uric acid level higher than 7.0 mg/dL.
• the results of blood uric acid level in the two treatment groups were analyzed by paired t-test of within-group changes.
• the baseline blood levels of uric acid in nine subjects of the diacerein group (2 females and 7 males) and twelve subjects of the placebo group (2 females and 10 males) in the hyperuricemia subgroup were above 7.0 mg/dL, and the mean levels were 8.06 mg/dL and 8.38 mg/dL respectively.
• FIG. 1 is a graph demonstrating blood uric acid levels in male patients treated with either diacerein or placebo; and Figure 2 is a graph demonstrating blood uric acid levels in female patients treated with either diacerein or placebo.
• Case 1 A 70-year-old woman with history of chronic gout and hyperuricemia was treated with aliopurinol since January 2, 2009. Before she was enrolled in the diacerein trial, her medical treatment was unsatisfactory, and her blood level of uric acid was 8.3 mg/dL in visit 1 (July 8, 2009).
• Case 2 A 66-year-old man with history of chronic gout and hyperuricemia was treated with aliopurinol since August 27, 2009. Before he was enrolled in the diacerein trial, his medical treatment was also unsatisfactory, and his blood level of uric acid was 9.5 mg/dL in visit 1 (December 18, 2009).

Landscapes

• Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Epidemiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Emergency Medicine (AREA)
• Diabetes (AREA)
• Physical Education & Sports Medicine (AREA)
• Hematology (AREA)
• Urology & Nephrology (AREA)
• Obesity (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (12)

Applications Claiming Priority (2)

Publications (1)

Family

ID=46796094

Family Applications (1)

Country Status (16)

Cited By (1)

Families Citing this family (15)

Citations (3)

Family Cites Families (4)

• 2012
  • 2012-03-07 AU AU2012229443A patent/AU2012229443B2/en not_active Ceased
  • 2012-03-07 BR BR112013022332A patent/BR112013022332A2/pt not_active IP Right Cessation
  • 2012-03-07 ES ES12757767.4T patent/ES2634562T3/es active Active
  • 2012-03-07 KR KR1020137026784A patent/KR101567885B1/ko not_active Expired - Fee Related
  • 2012-03-07 JP JP2013557816A patent/JP6012639B2/ja not_active Expired - Fee Related
  • 2012-03-07 CA CA2829101A patent/CA2829101C/en not_active Expired - Fee Related
  • 2012-03-07 PT PT127577674T patent/PT2683372T/pt unknown
  • 2012-03-07 MX MX2013010384A patent/MX350666B/es active IP Right Grant
  • 2012-03-07 EP EP12757767.4A patent/EP2683372B1/en not_active Not-in-force
  • 2012-03-07 WO PCT/US2012/027993 patent/WO2012125359A1/en not_active Ceased
  • 2012-03-07 CN CN201280012914.9A patent/CN103429236B/zh not_active Expired - Fee Related
  • 2012-03-07 US US13/414,264 patent/US8865689B2/en not_active Expired - Fee Related
  • 2012-03-07 RU RU2013145498/14A patent/RU2603050C2/ru not_active IP Right Cessation
  • 2012-03-09 TW TW101108193A patent/TWI505827B/zh not_active IP Right Cessation
  • 2012-03-12 AR ARP120100799A patent/AR085662A1/es unknown
• 2013
  • 2013-08-19 IL IL228030A patent/IL228030B/en active IP Right Grant

Patent Citations (4)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events